CRISPR Therapeutics CFO Prasad Raju Sells Shares

The transactions, totaling 10,000 common shares, were part of a prearranged plan adopted in August 2025.

December 24, 2025

Planned Share Sales Executed in Three Tranches

On December 22, 2025, Prasad Raju, Chief Financial Officer at CRISPR Therapeutics, sold 10,000 common shares of the company’s stock. The sales were carried out under a Rule 10b5-1 trading plan he adopted earlier this year, in August. These plans allow executives to schedule trades in advance, regardless of future developments.

The transactions broke down into three lots:

• 3,528 shares sold at a weighted average price of $55.10


• 5,472 shares sold at a weighted average price of $56.33


• 1,000 shares sold at a weighted average price of $56.88

In each case, the sales were executed across multiple trades within a narrow range of market prices.

Post-Transaction Holdings and Context

After completing these transactions, Raju retained direct ownership of 6,767 common shares in CRISPR Therapeutics. No derivative securities were reported in this filing.

These kinds of transactions are a standard part of how public company officers manage equity. Using a 10b5-1 plan allows them to establish a clear structure for future trades—one that stays in place even if new information emerges after the plan is set.

For CRISPR Therapeutics, the update reflects a scheduled adjustment in executive holdings. There were no indications of any changes to leadership or business direction. Raju continues to serve as CFO while the company remains focused on advancing its work in gene editing.